<?xml version="1.0" encoding="UTF-8"?>
<p id="p0075">Hispolon has potential to halt cell cycle in several cancer cells at G0/G1 and G2/M phase. In the human NB4 (promyelocytic leukemia) cells, hispolon caused cell cycle arrest at G0/G1with a marked reduction in CDK4, CDK2, cyclin E and cyclin D1 levels (
 <xref rid="bib15" ref-type="bibr">Chen et al., 2013</xref>). Hispolon induced G2/M arrest and inhibited the cell viability of glioblastoma U87MG cells by increasing the level of CDK inhibitor, p21 (
 <xref rid="bib4" ref-type="bibr">Arcella et al., 2017</xref>). Down-regulation of cyclins A and E contributed towards hispolon-stimulated S phase arrest with up-regulation of p27Kip1 and p21waf1/Cip1 expression in Hep3B cells (
 <xref rid="bib42" ref-type="bibr">Huang et al., 2011b</xref>). Hispolon has also been reported to induce S phase arrest in DU145Â cells by downregulating cyclin B1, cyclin D1 and CDK4 (
 <xref rid="bib60" ref-type="bibr">Masood et al., 2019</xref>). The distribution of hispolon treated lung cancer cells (A549 and H661) in different phase of cell cycle showed that hispolon treatment increased the accumulations of these cells in G0/G1 phase (
 <xref rid="bib89" ref-type="bibr">Wu et al., 2014</xref>). However, there is lack of evidences about phase specific cell cycle inhibitory potential of hispolon in various cancers such as whether hispolon halted cell cycle at G2, M, G0 or G1 phase which needs to be investigated in future studies.
</p>
